Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...